Thyrocare Board Approves Change to Insider Trading Code of Conduct

Thyrocare Technologies Limited recently announced that its Board of Directors has given the green light to an amendment in the company’s Code of Conduct. The updated Code, known as the “PIT Code,” is specifically aimed at overseeing trading activities carried out by designated persons and their immediate family members. This strategic move was made during a board meeting that took place on January 28, 2026.

The approval of this amendment underscores Thyrocare’s commitment to ensuring that all trading activities conducted by designated individuals adhere to fair practices and regulatory standards within the realm of securities trading. The amendment, put in place on January 28, 2026, is designed to offer more refined guidelines that govern the behavior of designated persons and their close relatives.

The key objective of this amendment lies in the effective regulation and monitoring of trading activities, particularly concerning the designated individuals and their immediate family members. This amendment, encapsulated in the updated “PIT Code,” is now available for public scrutiny on the company’s investor relations website. This release allows stakeholders the opportunity to gain an in-depth understanding of the revised regulations and guidelines set forth by Thyrocare.

In line with the code amendment, Thyrocare Technologies Limited continues to focus on upholding its commitment to ethical business practices and transparent operations. By providing a platform for internal and external stakeholders to review and evaluate the amended code, Thyrocare strengthens its transparency and accountability within the organization.

The amended Code of Conduct is a proactive step by Thyrocare to address and mitigate any potential issues related to insider trading. By clearly defining guidelines, the company aims to prevent unethical practices and ensure that trading is conducted in a fair, transparent, and compliant manner. The revised regulations are a testament to Thyrocare’s efforts to maintain regulatory compliance and promote a culture of integrity and accountability within the organization.

In conclusion, Thyrocare Technologies Limited’s recent approval of the amended Code of Conduct for Insider Trading signifies the company’s unwavering commitment to ethical practices and regulatory compliance. By providing transparent guidelines for designated persons and their immediate relatives, Thyrocare demonstrates its dedication to upholding fair trading practices and fostering trust among stakeholders.